Phenelzine and atenolol in social phobia

M. R. Liebowitz, F. Schneier, R. Campeas, J. Gorman, A. Fyer, Eric Hollander, J. Hatterer, L. Papp

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Seventy-four patients meeting DSM-III criteria for social phobia completed 4 or more weeks of double-blind, randomized treatment with the monoamine oxidase inhibitor phenelzine, the cardioselective beta-adrenergic blocker atenolol, or placebo. Sixty-four percent of the patients on phenelzine demonstrated moderate or marked improvement, compared to 30 percent on atenolol and 23 percent on placebo. Phenelzine was significantly more effective than atenolol or placebo, whereas the efficacy of atenolol and placebo did not differ significantly. Patients were also prospectively divided into generalized and discrete subtypes of social phobia. Phenelzine appeared to be a particularly effective treatment for the generalized form of social phobia. Atenolol may be useful for discrete forms of social phobia such as performance anxiety.

Original languageEnglish (US)
Pages (from-to)123-125
Number of pages3
JournalPsychopharmacology Bulletin
Volume26
Issue number1
StatePublished - 1990
Externally publishedYes

Fingerprint

Phenelzine
Atenolol
Placebos
Performance Anxiety
Adrenergic beta-Antagonists
Monoamine Oxidase Inhibitors
Diagnostic and Statistical Manual of Mental Disorders
Social Phobia
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology

Cite this

Liebowitz, M. R., Schneier, F., Campeas, R., Gorman, J., Fyer, A., Hollander, E., ... Papp, L. (1990). Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin, 26(1), 123-125.

Phenelzine and atenolol in social phobia. / Liebowitz, M. R.; Schneier, F.; Campeas, R.; Gorman, J.; Fyer, A.; Hollander, Eric; Hatterer, J.; Papp, L.

In: Psychopharmacology Bulletin, Vol. 26, No. 1, 1990, p. 123-125.

Research output: Contribution to journalArticle

Liebowitz, MR, Schneier, F, Campeas, R, Gorman, J, Fyer, A, Hollander, E, Hatterer, J & Papp, L 1990, 'Phenelzine and atenolol in social phobia', Psychopharmacology Bulletin, vol. 26, no. 1, pp. 123-125.
Liebowitz MR, Schneier F, Campeas R, Gorman J, Fyer A, Hollander E et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin. 1990;26(1):123-125.
Liebowitz, M. R. ; Schneier, F. ; Campeas, R. ; Gorman, J. ; Fyer, A. ; Hollander, Eric ; Hatterer, J. ; Papp, L. / Phenelzine and atenolol in social phobia. In: Psychopharmacology Bulletin. 1990 ; Vol. 26, No. 1. pp. 123-125.
@article{9455b438d3634fd48fbedf29ec1747a4,
title = "Phenelzine and atenolol in social phobia",
abstract = "Seventy-four patients meeting DSM-III criteria for social phobia completed 4 or more weeks of double-blind, randomized treatment with the monoamine oxidase inhibitor phenelzine, the cardioselective beta-adrenergic blocker atenolol, or placebo. Sixty-four percent of the patients on phenelzine demonstrated moderate or marked improvement, compared to 30 percent on atenolol and 23 percent on placebo. Phenelzine was significantly more effective than atenolol or placebo, whereas the efficacy of atenolol and placebo did not differ significantly. Patients were also prospectively divided into generalized and discrete subtypes of social phobia. Phenelzine appeared to be a particularly effective treatment for the generalized form of social phobia. Atenolol may be useful for discrete forms of social phobia such as performance anxiety.",
author = "Liebowitz, {M. R.} and F. Schneier and R. Campeas and J. Gorman and A. Fyer and Eric Hollander and J. Hatterer and L. Papp",
year = "1990",
language = "English (US)",
volume = "26",
pages = "123--125",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "1",

}

TY - JOUR

T1 - Phenelzine and atenolol in social phobia

AU - Liebowitz, M. R.

AU - Schneier, F.

AU - Campeas, R.

AU - Gorman, J.

AU - Fyer, A.

AU - Hollander, Eric

AU - Hatterer, J.

AU - Papp, L.

PY - 1990

Y1 - 1990

N2 - Seventy-four patients meeting DSM-III criteria for social phobia completed 4 or more weeks of double-blind, randomized treatment with the monoamine oxidase inhibitor phenelzine, the cardioselective beta-adrenergic blocker atenolol, or placebo. Sixty-four percent of the patients on phenelzine demonstrated moderate or marked improvement, compared to 30 percent on atenolol and 23 percent on placebo. Phenelzine was significantly more effective than atenolol or placebo, whereas the efficacy of atenolol and placebo did not differ significantly. Patients were also prospectively divided into generalized and discrete subtypes of social phobia. Phenelzine appeared to be a particularly effective treatment for the generalized form of social phobia. Atenolol may be useful for discrete forms of social phobia such as performance anxiety.

AB - Seventy-four patients meeting DSM-III criteria for social phobia completed 4 or more weeks of double-blind, randomized treatment with the monoamine oxidase inhibitor phenelzine, the cardioselective beta-adrenergic blocker atenolol, or placebo. Sixty-four percent of the patients on phenelzine demonstrated moderate or marked improvement, compared to 30 percent on atenolol and 23 percent on placebo. Phenelzine was significantly more effective than atenolol or placebo, whereas the efficacy of atenolol and placebo did not differ significantly. Patients were also prospectively divided into generalized and discrete subtypes of social phobia. Phenelzine appeared to be a particularly effective treatment for the generalized form of social phobia. Atenolol may be useful for discrete forms of social phobia such as performance anxiety.

UR - http://www.scopus.com/inward/record.url?scp=0025171532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025171532&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 123

EP - 125

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 1

ER -